分化型甲状腺癌肺转移生长速率评估:实体瘤疗效评价标准还是倍增时间?
本研究纳入1995至2013年间接受全甲状腺切除及高剂量放射性碘治疗的分化型甲状腺癌伴大结节性肺转移患者44例,比较RECIST进展时间、平均肿瘤体积倍增时间(midDT)与甲状腺球蛋白倍增时间(TgDT)对疾病特异性生存(DSS)的预测价值。中位随访6.8年,三种标准评估的生长速率均与DSS显著相关,其中midDT预测价值最高(变异解释比例33.6%)。
要点
- RECIST评估12例(27.3%)为快速进展,进展时间<1年。
- midDT≤1年者9例(20.5%),TgDT<1年者5年DSS为42.9%。
- midDT≤1年者5年DSS为29.6%,进展时间<1年者为50.0%。
核心结论
- 在评估分化型甲状腺癌肺转移生长速率的各标准中,midDT对DSS的预测能力最强,优于RECIST和TgDT。
- 作者认为肺转移诊断后第一年内至少行三次连续胸部CT扫描有助于早期发现快速进展患者,并为启动全身治疗提供客观指导。
研究设计与样本
- 纳入1995至2013年间接受全甲状腺切除及高剂量放射性碘治疗的分化型甲状腺癌伴大结节性(≥1 cm)肺转移患者44例。
- 测量每位患者的RECIST进展时间、两个优势靶肺病灶的平均肿瘤体积倍增时间(midDT)及甲状腺球蛋白倍增时间(TgDT),评估其与疾病特异性生存(DSS)的关联。
主要发现
- 靶肺转移结节初始最大直径中位数1.3 cm,肺转移诊断后中位随访6.8年。
- 基于RECIST,12例(27.3%)显示快速肿瘤进展,进展时间<1年。
- 基于midDT,9例(20.5%)midDT≤1年,显示快速肿瘤进展。
- 33例甲状腺球蛋白抗体阴性患者中7例(21.2%)midDT<1年。
- 三种标准评估的生长速率均与DSS显著相关;midDT对DSS预测价值最高,变异解释比例33.6%。
关键数值与推荐
- RECIST快速进展定义为进展时间<1年,本组12例(27.3%)。
- midDT快速进展定义为midDT≤1年,本组9例(20.5%)。
- TgDT<1年者5年DSS为42.9%。
临床怎么用
- 作者建议肺转移诊断后第一年内至少行三次连续胸部CT扫描,以助早期发现快速进展患者并为启动全身治疗提供客观指导。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Estimating the growth rate of lung metastases for the treatment of patients with metastases of differentiated thyroid carcinoma (DTC) is important. This study aimed to evaluate survival outcomes according to different criteria for estimating the growth rate of lung metastases. Methods: Patients with macronodular (≥1 cm) lung metastases of DTC who underwent total thyroidectomy and high-dose radioactive iodine therapy between 1995 and 2013 were enrolled. The time to progressive disease (PD) by the Response Evaluation Criteria in Solid Tumors (RECIST), average tumor volume doubling time of the two dominant target lung lesions (midDT), and thyroglobulin doubling time (TgDT) were measured in each patient, and their association with disease-specific survival (DSS) was evaluated. Results: Forty-four patients with target lung metastatic nodules with an initial maximal diameter of 1.3 cm (median) were followed-up for a median of 6.8 years after the diagnosis of lung metastases. Based on RECIST, 12 patients (27.3%) showed fast tumor progression, with time to PD <1 year. When assessed by midDT, nine patients (20.5%) had midDT ≤1 year, showing rapid tumor progression. Seven of 33 patients (21.2%) who were negative for thyroglobulin antibody had midDT <1 year. Growth rates assessed by all three criteria were significantly associated with DSS. However, midDT had the highest predictive value for DSS, with a proportion of variation explained of 33.6%. Five-year DSS was 29.6% in patients with midDT ≤1 year, 50.0% in patients with time to PD <1 year, and 42.9% in patients with TgDT <1 year. Conclusions: Among the different criteria for estimating the growth rate of metastases in patients with lung metastases of DTC, midDT was the most powerful for predicting DSS, in comparison with RECIST and TgDT. Performing at least three serial chest computed tomography scans during the first year from the diagnosis of lung metastases can facilitate early detection of patients with rapid tumor progression and provide objective guidance for initiation of systemic therapy.
引用
- Song E, Ahn J, Jeon MJ, et al. Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time? Thyroid. 2020. PMID: 31880976. doi:10.1089/thy.2019.0341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。